- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Government caps prices of 18 life saving drugs
In order to make life saving drugs used to treat cancer, inflammation, infections, and others, the government has capped the prices of 18 more formulation drugs. This is in lieu of making essential drugs more affordable, with 500 drugs already covered under the price control list.The move also brings pharmaceutical companies, including Abbott Healthcare, Cipla, Cadila Pharmaceuticals,...
In order to make life saving drugs used to treat cancer, inflammation, infections, and others, the government has capped the prices of 18 more formulation drugs. This is in lieu of making essential drugs more affordable, with 500 drugs already covered under the price control list.
The move also brings pharmaceutical companies, including Abbott Healthcare, Cipla, Cadila Pharmaceuticals, Dr Reddy's Laboratories and Torrent Pharma, under the jurisdiction imposed for the price control.
Last month NPPA had capped the prices of 39 formulation packs, including those used to treat various diseases such as diabetes and digestive disorders, as confirmed by PTI.
In a statement, drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) said, "it has fixed/revised the prices in respect of 39 formulation packs ... and one corrigendum ... related to the ceiling price fixation of Paclitaxel injection."
As per the notification, the prices of formulations including Diclofenac Sodium, Clotrimazole, Mesalamine, Omeprazole+Domperidone and Vancomycin have been fixed.
The move also brings pharmaceutical companies, including Abbott Healthcare, Cipla, Cadila Pharmaceuticals, Dr Reddy's Laboratories and Torrent Pharma, under the jurisdiction imposed for the price control.
Last month NPPA had capped the prices of 39 formulation packs, including those used to treat various diseases such as diabetes and digestive disorders, as confirmed by PTI.
In a statement, drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) said, "it has fixed/revised the prices in respect of 39 formulation packs ... and one corrigendum ... related to the ceiling price fixation of Paclitaxel injection."
As per the notification, the prices of formulations including Diclofenac Sodium, Clotrimazole, Mesalamine, Omeprazole+Domperidone and Vancomycin have been fixed.
Next Story